| News

Idorsia receives payment of 45 million US dollars

12.05.2020

The Allschwil-based pharmaceutical company Idorsia receives a payment of 45 million US dollars as part of an agreement with Neurocrine Biosciences and shall also be entitled to claim milestone payments in future. Neurocrine has exercised a licensing option for a drug developed by Idorsia to treat epilepsy.

Idorsia headquarter in Allschwil (img: Idorsia)

Idorsia has developed a T-type calcium channel blocker in the form of ACT-709478 that should facilitate treatment of a rare form of epilepsy in children. According to a press release, Idorsia has agreed a licensing agreement with Neurocrine Biosciences. As the US company has now decided to take up its option to license the global development and marketing rights to ACT-709478, Idorsia is set to receive fixed payments as part of the agreement.

In this context, the company based in Allschwil receives an upfront payment of 45 million US dollars. Moreover, Idorsia will be entitled to claim milestone payments up to a potential total of 365 million US dollars in addition to tiered royalties dependent on net sales figures. Neurocrine Biosciences is already planning to launch a Phase II study in the second half of 2020.

“If the efficacy of our selective T-type calcium channel blocker seen in preclinical models is confirmed in children with rare pediatric epilepsy, it could transform the life of children with this disease”, comments Martine Clozel, Chief Scientific Officer of Idorsia, in the press release. Furthermore, this is a case where collaborating with a partner allows greater progress to be made in further development processes.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Novartis Campus
Basel Area Business & Innovation, Switzerland Innovation Park

Switzerland Innovation Park Basel Area Site Novartis Campus

We are happy to present our latest addition to the Switzerland Innovation Park Basel Area: Our site on the Novartis Campus dedicated to digital health provides a focal point to a unique community of digital healthcare experts.

Read More
Basel Area Business & Innovation, Switzerland Innovation Park

The innovation and enterprise campus GRID is filling up

Two institutes from the University of Basel and a pharmaceutical company are relocating to the GRID innovation and enterprise campus, which is currently under construction at BaseLink in Allschwil. The new building will also contain the headquarters of the Switzerland Innovation Park Basel Area in future.

Read More
Basel Area Business & Innovation, Innovation

Artidis ends successful study

Artidis, a startup from Basel, has developed a nanotechnology platform that can be used for cancer diagnosis, among other things. The platform has now been tested in a study that was able to achieve its primary endpoint.

Read More
Basel Area Business & Innovation, Innovation

Startup Academy celebrates anniversary

Startup Academy is on the road to success ten years after being founded. The initiative has supported 280 startups to date. The project was originally started in Basel and is now represented at several locations in Switzerland with plans for further growth.

Read More
Basel Area Business & Innovation, Invest

Syngenta grows strongly and stays true to Basel

Syngenta AG, Adama and Sinochem are to be united under the umbrella of the new Syngenta Group. The group is headquartered in Basel and employs around 48,000 staff across over 100 countries.

Read More
Basel Area Business & Innovation, Innovation

Tolremo raises additional funding

The Muttenz-based biotechnology company Tolremo Therapeutics has raised an additional 4.7 million Swiss francs as part of a financing round. The company develops cancer therapies for precision medicine and is now driving forward clinical development.

Read More
1 2 3 31

Do you have a question? We'd like to hear from you.